Table 2.
Factors associated with prognosis in univariate and multivariate analyses
| Variables |
Univariate analysis |
Multivariate analysis |
Variables |
Univariate analysis |
Multivariate analysis |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | ||||
| Overall survival | Overall survival | ||||||||||||||
| Str-TIL | Str-TIL (per 10% increase) | 0.79 | 0.71–0.89 | <0.001 | 0.86 | 0.77–0.97 | 0.01 | It-TIL | It-TIL (per 10% increase) | 0.78 | 0.68–0.89 | <0.001 | 0.86 | 0.75–0.99 | 0.03 |
| Age (years) | ≥50 | 1.00 | Age (years) | ≥50 | 1.00 | ||||||||||
| <50 | 0.78 | 0.54–1.13 | 0.19 | <50 | 0.79 | 0.54–1.14 | 0.20 | ||||||||
| cStage | I–II | 1.00 | cStage | I–II | 1.00 | 1.00 | |||||||||
| III | 2.33 | 1.59–3.4 | <0.001 | 1.44 | 0.96–2.15 | 0.08 | III | 2.30 | 1.57–3.36 | <0.001 | 1.43 | 0.95–2.13 | 0.08 | ||
| Histotype | Ductal | 1.00 | Histotype | Ductal | 1.00 | ||||||||||
| Lobular | 0.80 | 0.11–5.75 | 0.83 | Lobular | 0.80 | 0.11–5.76 | 0.83 | ||||||||
| Other | 0.42 | 0.13–1.32 | 0.14 | Other | 0.42 | 0.13–1.32 | 0.14 | ||||||||
| Grade | 1–2 | 1.00 | Grade | 1–2 | 1.00 | ||||||||||
| 3 | 0.95 | 0.55–1.63 | 0.85 | 3 | 0.95 | 0.55–1.64 | 0.86 | ||||||||
| Nodal status after neoadjuvant chemotherapy | Neg | 1.00 | Nodal status after neoadjuvant chemotherapy | Neg | 1.00 | 1.00 | |||||||||
| Pos | 4.53 | 2.9–7.07 | <0.001 | 3.52 | 2.21–5.58 | <0.001 | Pos | 4.61 | 2.94–7.25 | <0.001 | 3.56 | 2.23–5.69 | <0.001 | ||
| Residual tumor size | ≤2 cm | 1.00 | Residual tumor size | ≤2 cm | 1.00 | 1.00 | |||||||||
| >2 cm | 2.64 | 1.77–3.93 | <0.001 | 1.54 | 1–2.36 | 0.05 | >2 cm | 2.65 | 1.77–3.97 | <0.001 | 1.65 | 1.07–2.53 | 0.02 | ||
| Neo | A-based/other | 1.00 | Neo | A-based/other | 1.00 | ||||||||||
| A + T-based | 0.88 | 0.6–1.29 | 0.52 | A + T-based | 0.90 | 0.61–1.32 | 0.59 | ||||||||
| Neo + Adj | A + T | 1.00 | Neo + Adj | A + T | 1.00 | ||||||||||
| Other | 0.87 | 0.59–1.28 | 0.48 | Other | 0.85 | 0.58–1.26 | 0.43 | ||||||||
| Metastasis-free survival | Metastasis-free survival | ||||||||||||||
| Str-TIL | Str-TIL (per 10% increase) | 0.79 | 0.71–0.88 | <0.001 | 0.86 | 0.77–0.96 | 0.01 | It-TIL | It-TIL (per 10% increase) | 0.77 | 0.68–0.88 | <0.001 | 0.85 | 0.75–0.98 | 0.02 |
| Age (years) | ≥50 | 1.00 | Age (years) | ≥50 | 1.00 | ||||||||||
| <50 | 0.75 | 0.53–1.06 | 0.11 | <50 | 0.75 | 0.53–1.07 | 0.12 | ||||||||
| cStage | I–II | 1.00 | cStage | I–II | 1.00 | 1.00 | |||||||||
| III | 2.35 | 1.63–3.39 | <0.001 | 1.45 | 0.98–2.13 | 0.06 | III | 2.32 | 1.61–3.35 | <0.001 | 1.44 | 0.98–2.12 | 0.06 | ||
| Histotype | Ductal | 1.00 | Histotype | Ductal | 1.00 | ||||||||||
| Lobular | 0.75 | 0.1–5.34 | 0.77 | Lobular | 0.74 | 0.1–5.33 | 0.77 | ||||||||
| Other | 0.36 | 0.11–1.13 | 0.08 | Other | 0.36 | 0.11–1.13 | 0.08 | ||||||||
| Grade | 1–2 | 1.00 | Grade | 1–2 | 1.00 | ||||||||||
| 3 | 1.00 | 0.59–1.71 | 1.00 | 3 | 1.01 | 0.59–1.72 | 0.98 | ||||||||
| Nodal status after neoadjuvant chemotherapy | Neg | 1.00 | Nodal status after neoadjuvant chemotherapy | Neg | 1.00 | 1.00 | |||||||||
| Pos | 5.02 | 3.25–7.75 | <0.001 | 4.00 | 2.55–6.28 | <0.001 | Pos | 5.10 | 3.28–7.93 | <0.001 | 4.00 | 2.54–6.32 | <0.001 | ||
| Residual tumor size | ≤2 cm | 1.00 | Residual tumor size | ≤2 cm | 1.00 | 1.00 | |||||||||
| >2 cm | 2.57 | 1.76–3.76 | <0.001 | 1.47 | 0.98–2.22 | 0.06 | >2 cm | 2.57 | 1.75–3.78 | <0.001 | 1.58 | 1.05–2.38 | 0.03 | ||
| Neo | A-based/other | 1.00 | Neo | A-based/other | 1.00 | ||||||||||
| A + T-based | 0.87 | 0.61–1.26 | 0.47 | A + T-based | 0.89 | 0.62–1.28 | 0.53 | ||||||||
| Neo + Adj | A + T | 1.00 | Neo + Adj | A + T | 1.00 | ||||||||||
| Other | 0.87 | 0.6–1.26 | 0.47 | Other | 0.86 | 0.59–1.24 | 0.41 | ||||||||
Str-TIL, stromal tumor-infiltrating lymphocytes; It-TIL, intratumoral tumor-infiltrating lymphocytes; HR, hazard ratio; CI, confidence interval; cStage, clinical stage at diagnosis; Neg, negative; Pos, positive; Neo, neoadjuvant treatment; A, anthracycline; T, taxane; adj, adjuvant treatment.